Literature DB >> 3904854

Infection and Branhamella catarrhalis.

D T McLeod, F Ahmad, M A Calder.   

Abstract

Of the Gram-negative cocci found in the nasopharynx to which any pathogenic status can be attributed, Neisseria meningitidis and Neisseria (Branhamella) catarrhalis have gained significant notoriety. Traditionally, B. catarrhalis is regarded as a nasopharyngeal commensal and thus there is, in general, considerable reluctance to accept that B. catarrhalis may be a pathogen when it is seen. Hence, it is under-reported or totally ignored though there is more awareness regarding its pathogenic potential, particularly as an increasingly high incidence of beta lactamase producing strains is being reported from many countries. The importance of this development concerns the choice of routine antibiotic therapy as ampicillin, to which this organism was previously sensitive, may no longer be effective.

Entities:  

Mesh:

Year:  1985        PMID: 3904854

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Labile type-specific antigen of Moraxella catarrhalis.

Authors:  S J Norkus; J W Vennes
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

2.  Efficacy and tolerability of cefixime in otitis media. A multicentre study in over 25,000 children.

Authors:  D H Wu
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 3.  Branhamella catarrhalis: an organism gaining respect as a pathogen.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1990-10       Impact factor: 26.132

4.  Epidemiological typing of Moraxella catarrhalis by using DNA probes.

Authors:  D Beaulieu; S Scriver; M G Bergeron; D E Low; T R Parr; J E Patterson; A Matlow; P H Roy
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

5.  Evidence of lectin-mediated adherence of Moraxella catarrhalis.

Authors:  J Kellens; M Persoons; M Vaneechoutte; F van Tiel; E Stobberingh
Journal:  Infection       Date:  1995 Jan-Feb       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.